Transforming Transplant-Eligible Newly Diagnosed Multiple Myeloma: From Real-World Evidence to Clinical Practice

Luciano Costa, MD, PhD and Timothy Schmidt, MD introduce treatment regimen options and risk stratification for patients with transplant-eligible NDMM.

Thoughtful discussion centered around recently presented updates to the MASTER trial.

A summary of updates from the GRIFFIN trial evaluating D-RVd in clinically relevant NDMM patient subgroups.

Subject-matter experts share their perspectives on treatment selection for patients with NDMM.

Experienced clinicians share their perspectives on maintenance therapy for patients with NDMM.

Dr. Costa and Dr. Schmidt consider promising emergent treatment options and current unmet needs in the NDMM treatment landscape.

Experts in the multiple myeloma space discuss recent developments and how to implement new practices in real-world settings.